Brief: Akeso Announces First Patient Dosed In Phase 3 Trial Of Ivonescimab Versus Tislelizumab
18/08/2023 13:05
Aug 18 (Reuters) - Akeso Inc 9926.HK :
* AKESO ANNOUNCED FIRST PATIENT DOSED IN PHASE 3 TRIAL OF
IVONESCIMAB VERSUS TISLELIZUMAB FOR FIRST-LINE TREATMENT OF
SQUAMOUS NSCLC
* AKESO - INTERNATIONAL MULTICENTER PHASE III CLINICAL TRIAL
OF
IVONESCIMAB FOR THIS SPECIFIC INDICATION IS CURRENTLY ONGOING
* AKESO - IVONESCIMAB IS CURRENTLY ENGAGED IN MULTIPLE PHASE
III
CLINICAL TRIALS WORLDWIDE
Source text for Eikon: ID:nPnlDNPda
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals